Advisory Services Network LLC decreased its position in shares of Sanofi (NYSE:SNY) by 0.9% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 8,674 shares of the company’s stock after selling 77 shares during the period. Advisory Services Network LLC’s holdings in Sanofi were worth $363,000 at the end of the most recent reporting period.
A number of other large investors also recently modified their holdings of the stock. JFS Wealth Advisors LLC increased its stake in shares of Sanofi by 3.5% in the second quarter. JFS Wealth Advisors LLC now owns 3,961 shares of the company’s stock worth $166,000 after buying an additional 134 shares during the last quarter. BlackRock Institutional Trust Company N.A. bought a new stake in shares of Sanofi during the first quarter worth $175,000. Rehmann Capital Advisory Group increased its stake in shares of Sanofi by 0.5% in the second quarter. Rehmann Capital Advisory Group now owns 5,571 shares of the company’s stock worth $233,000 after buying an additional 26 shares during the last quarter. Flow Traders U.S. LLC increased its stake in shares of Sanofi by 1.3% in the first quarter. Flow Traders U.S. LLC now owns 6,128 shares of the company’s stock worth $246,000 after buying an additional 81 shares during the last quarter. Finally, Cypress Wealth Advisors LLC bought a new stake in shares of Sanofi during the first quarter worth $247,000. 9.42% of the stock is currently owned by institutional investors.
Shares of Sanofi (NYSE:SNY) traded up 0.05% on Friday, reaching $38.53. The company had a trading volume of 1,609,571 shares. Sanofi has a 52 week low of $37.41 and a 52 week high of $51.88. The company’s 50-day moving average price is $38.79 and its 200 day moving average price is $40.45. The firm has a market capitalization of $99.18 billion, a P/E ratio of 21.36 and a beta of 0.98.
A number of equities research analysts recently weighed in on SNY shares. Leerink Swann reaffirmed a “buy” rating on shares of Sanofi in a research report on Monday, September 26th. TheStreet upgraded Sanofi from a “hold” rating to a “buy” rating in a research note on Wednesday, July 27th. Berenberg Bank upgraded Sanofi from a “hold” rating to a “buy” rating in a research note on Thursday, September 8th. Zacks Investment Research upgraded Sanofi from a “sell” rating to a “hold” rating in a research note on Monday, July 25th. Finally, Jefferies Group reiterated a “hold” rating on shares of Sanofi in a research note on Wednesday, September 14th. Three investment analysts have rated the stock with a sell rating, nine have assigned a hold rating and five have assigned a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average price target of $60.50.
Sanofi, formerly Sanofi-Aventis, is a healthcare company engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company operates through three segments: Pharmaceuticals, Human Vaccines (Vaccines) and Animal Health. The Pharmaceuticals segment consists of research, development, production and marketing of medicines, including those originating from Genzyme Corporation.
Want to see what other hedge funds are holding SNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sanofi (NYSE:SNY).
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.